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OraJ ontraceptives: Nature, Use 
And Physiological Effects* 
ANNE R. MALEDON, B.S. 
"Within a few years 80 million women on 
this continent alone will be taking 'the 
pill'!" 
John Gillies, Medical World 
Approximately 5,000,000 Ameri­
can women are now using oral 
contraceptives. "Never have so many 
people taken such potent drugs vol­
untarily over such a protracted pe­
riod for an objective other than the 
control of disease. "1 So spoke a spe­
cial advisory committee of the U.S. 
Food and Drug Administration. 
But is "the pill" safe to take? To 
this question came the answer: "The 
committee finds no adequate scien­
tific data, at this time, proving these 
compounds unsafe for human use."2 
The tone of reservation implicit in 
the double negative of the statement 
is not surprising. Even without 
reading the Time magazine report, 
a non-professional layman knows 
that medicines "cannot be certified 
as completely safe until after years 
of detailed study on tens of thou­
sands of patients."3 And even then 
certification can be valid only if 
large scale, careful reporting is 
adhered to. 
As "the pill" moves into its second 
decade of consumption, however, 
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interest in it grows apace. 
b er of aspects, particul£ 
moral and socio-economic, 
triguing. But this paper c 
elusively with the natl 
and physiological effects 
contraceptives. 
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All oral contraceptives consist 
basically of two synthetic .eroids, 
an estrogen and a progestc 'n. Se-
lection of one of two rithetic 
estrogens and one of ten gesto-
gens accounts for the trad names. 
If the two steroids are adrr 1istered 
together for twenty days, · e ther­
apy is called combinatior If an 
estrogen is given for fiftE. 1 days, 
then a progestogen for the tst five, 
the therapy is called sequen· il.4 The 
combined steroids are Jld as 
Enovid ( the original "pill" Ortho­
N ovum, Norinyl, Prov, .t, and 
Norlestin. The estrogen-pr< ;estogen 
composite goes by the r· :mes of 
Oracon and C-Quens, br h more 
recently developed drugs. 1 ,e diff�r­
ence? Theoretically, the s-·quenual 
therapy resembles the secr..:tion se­
quence as it occurs in t,1e body. 
Practically, however, neithLr type of 
therapy replicates the natvral proc­
ess of secretion of the sex hormones, 
nor are all the synthetic steroids 
chemically identical with the natural 
steroid hormones of either class. In 
efficacy and general side effects, 
none the less, the combined and 
sequential forms are similar. 
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USES 
"The pill," composed of synthetic 
steroids, has several uses. Paradoxi­
cally, it is employed for both con­
ceptive and contraceptive purposes. 
As a contraceptive agent, it is un­
questionably effective. In fact, its 
99+% efficiency rate is becoming a 
dictum. Over and above their effi­
cacy as contraceptives, "the pills" 
have proved remedial for gyneco­
logical orders. Irregular menses, amenorrhea, dysmenorrhea, endo­
metrios.is, and menopausal complaints 
are some of these. Obviously, it will 
be some time before the overall ther­
apeutic value of "the pills" is estab­
lished. Even so, oral contraceptives 
to date have been an important 
medical tool. 
PHYSIOLOGICAL EFFECTS 
Ironically, despite their 99+% 
effectiveness when taken as directed 
the mode of action of oral contra� 
ceptives is littl� understood. Author­
ities are certain of only the obvious: 
· that administered daily from the
fifth through the twenty-fourth day
of the menstrual cycle, "the pill"
will prevent conception and produce
an artificial menstrual period re­
sembling the natural one in both
duration and quantity of flow.
Many authorities believe that ovu­
lation is prevented. In support of
this view, Edwin DeCosta, writing
in ].A.M.A., postulates that the two
hormones in "the pill" suppress ovu­
lation by acting on the pituitary
�land.5 "The pill" inhibits the pitu­itary from secreting the gonado­
trophic hormones, FSH and LH.
Since these two hormones are not
secreted, the egg is not "prepared"
for ovulation, and the process does
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not occur. R L. Holmes in the 
journal Lancet, states a different 
opinion, namely, that LH release is 
not blocked, and that suppression 
of FSH has neither been proved nor 
disproved.6 Experiments with ani­
mals do indicate that ovulation is 
suppressed, but since ovulation in 
animals is not identical with that of 
women, what may be true of 
animals is not necessarily true of 
humans, in this regard. Other 
investigators .have suggested other 
mechanisms by which oral con­
traceptives may produce functional 
sterility (There is some evidence 
of permanent sterility, incidentally, 
which may work a hardship for 
those women who plan to have 
children after a year or two on 
"the pill"). These mechanisms may 
be either a direct influence on the 
ovary, or a deleterious action on the 
germ cells themselves.7, 8 
Whatever the uncertainty regard­
ing the mode of action of "the pills," 
their influence on the body's natural 
hormone balance is well known. 
The estrogen-progestogen combina­
tions taken daily lead also to altera­
tions of the harmonics of several 
other systems including the neuro­
logical, which are concerned in 
reproductive and behavioral physi­
ology.9 Experiments with estrogen­
progestogen i n  animals a l so  
demonstrate that pituitary tumors 
are frequently found after prolonged 
treatment. 
The most obvious effects of these 
contraceptive agents, however, is a 
local one, i.e., the radical change 
produced in the endometrium. In 
contrast to a normal endometrium, 
characterized by vascular tissue 
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supplied with many glands, the 
progestogen-treated endometrium ex­
h i  b i t s  only a f ew  i nvolute d  
glands, poor vascularity, and stromal 
edema.1° Collectively, these changes 
produce the appearance of aging of 
the endometrium.11 Although neo­
plastic relationships as such will be 
dealt with later on in this paper, 
attention should be called here to 
the observation that "in predisposed 
individuals, the unopposed action of 
estrogenic substances - and all oral 
contraceptives are estrogenic- for 
considerable periods of time will re­
sult in endometrial adenomatous 
hyperplasfa, carcinoma in situ, and 
eventually in carcinoma."12
Over and above the influence of 
oral contraceptives on the endocrine 
and other systems in · general, and 
the uterine lining in particular, their 
action is associated with liver dam­
age. The estrogen component of "the 
pill" is known to impair the excre­
tory function of the liver; it may 
damage liver cells directly.rn Tests 
generally employed in medical prac­
tice to detect hepatic impairment 
are I) serum transaminase level, 
2) bromsulphthalein retention, 3)
serum alkaline phosphatase levels.
Abnormally high serum transami­
nase levels and bromsulphthalein
retention appear in almost every 
tested user of "the pill."14,15 ,16,11
Stroll noted an increase in serum 
transaminase from the normal I 0-40
units to 200 units, and in serum iso­
citric dehydrogenase levels from the
normal 3-10 units to 77-165 units.ts
Bromsulphthalein retention has been 
known to increase to pathological
levels within two weeks during "pill" 
use. Hepatic malfunction may de-
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velop in as few as 28 days, )ne 
cycle of treatment. 
In 1963, Enovid was bn ght 
under criticism for its susf �ted 
relationship with thromboembc ;sm. 
This is not astonishing, for thrc 1bo­
embolism has been associate vith 
pregnancy, during which time 1igh 
concentrations of estrogens an, pro­
gestins appear in the blood. lhat 
brought "the pill" to mm idity 
headlines, however, was the �port 
that more than 350 cases of t rom­
boembolism had occurred in I 10vid 
users in little over a twelve .onth 
period. At this point, the FI \ ap­
pointed the Wright Commi 2e to 
investigate these cases; the c, ,1mit­
tee reported its findings l; �r in 
1963. Wright and his work1 s tal­
lied a 12.1 % incidence r fatal 
thromboemboli among Enovi users, 
as compared with the 8.4% ate in 
the general population.19 1 ,e fig­
ures became statistically rn1 e sig­
nificant when age group were 
considered. In women use s who 
were over thirty-five, there was a 
disproportionately greater ir ;idence 
of thromboembolism. Usi.:g the 
same statistics as Wright, � assouf 
calculated fatality rates on ,, differ­
ent basis. He used "woma1,-years" 
(twelve women taking the drug for 
one month each) as the unit of 
exposure. This was the basis on 
which most of the favorable statistics 
on Enovid had been calculated. 
According to Kassouf's calculations, 
the death rate from thromboembo­
lism was 22.3 per million per 
year, nearly three times as high as 
that in the population at large.20
Not w i t hs tanding, the Wright 
Committee concluded that a defi-
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nite cause-effect relationship between 
"the pill" and thromboemboli is yet 
to be statistically demonstrated. Still 
to be demonstrated, however, is the 
absence of cause and effect correla­
tion between "pill" and clot. In the 
interim, though, it is not irrelevant 
to note that oral progestins are being 
used in the treatment of hemorrhagic
disorders.2l
A second circulatory phenomenon 
observed in "the pill" users is an 
increased venous distensibility simi­
lar to that observed in pregnancy. 
Over a period of time, the valves 
which prevent the backflow of blood 
become incompetent, and allow the 
blood to stagnate in the vessels, 
thereby providing opportune envi­
ronment for thrombophlebitis and/or 
thromboemboli. As Eugene F. Dia­
mond points out, even those who 
disagree on the association between 
"the pill" and thromboemboli, 
"fairly uniformly admit the associa­
tion between oral progestins and 
thrombophlebitis."22 And how many 
cardiovascular specialists would deny 
that thrombophlebitis at least pre­
disposes vessels to the formation of 
clots? 
Finally, estrogenic agents, even 
naturally occurring ones, have been 
known since the turn of the century 
to be associated with malignancies. 
To what extent malignant neo­
plasms are effected or affected by 
estrogens depends in part upon· 
the type of neoplasm23 ·24 and the 
amount of estrogen administered. 2;; 
In certain predisposed humans and 
research animals, estrogen has been 
known to "cause" cancer. This is 
usually a gradual process, which 
begins with the alteration of the 
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hormone balance, which in turn 
produces cellular changes in the 
ovary or other parts of the body, 
and eventually ends with tumors.26 
A much more common concomitant 
of estrogen therapy, however, is a 
pronounced growth of already exist­
ing tumors. Very small breast car­
cinomas have developed with great 
rapidity during oral contraceptive 
use, according to Shipman.27 More­
over, the progestogen component of 
"the pill" ma,y increase metastasis 
of an initially localized malignancy.28
Above and beyond the major ill­
effects so far mentioned, oral con­
traceptives may induce so-called 
minor side-effects:29 ,30,31 ,32 l) break­
through bleeding or "spotting," 2) 
nausea; 3) weight-gain - up to ten 
pounds, 4) breast soreness and en­
largement, 5) acne, 6) headache, 7) 
dizziness, 8) depression and fatigue, 
9) irritability, IO) edema, 11) aug­
mented pre-menstrual tension, 12)
stoppage of lactation, 13) insomnia,
14) increased facial pigmentation,
IS) leg cramping, 16) rash/itching,
17) amenorrhe'a, 18) loss or growth
of body hair, 19) 'growth of uterine
fibroids, 20) virilization of the fe­
male infant. Many of these are, ad­
mittedly, more disagreeable than
dangerous. A few, however, carry
a subtle threat. Two of these only
will be treated here.
First, break-through or intermens­
trual bleeding. Under ordinary con­
ditions, unusual bleeding may be 
symptomatic of malignancy. Since, 
however, spotting is to be expected 
during oral contraceptive use, both 
patient and doctor may dismiss such 
bleeding as unimportant. G. H. 
Green highlights the danger latent 
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in such a dismissal: a young woman 
of thirty had complained of spotting 
while taking "the pill." The attend­
ing physician had attached no sig­
nificance to the event, because the 
woman had had a cervical smear 
within the year. That six months 
later she was found to have a far 
advanced malignancy33 would seem
to be somewhat alarming. 
The second side-effect deserving 
special comment is virilization of the 
female infant. Not always, but fre­
quently enough, oral contraceptives 
taken during the early months of 
pregnancy affect the female foetus. 
The masculinizing effect is usually 
in the form of an enlarged clitoris, 
of which the implications for the 
child's future may be more than 
incidental. 
Having come this far, let us take 
a backward glance at these data on 
"the pills." They are effective as 
contraceptives to the extent of almost 
100%. They are useful as gyneco­
logical tools. Such is medical con­
sensus about their efficacy. About 
their safety, however, there is not 
such unanimity. Even so, suppose 
that all the side-effects, major and 
minor, are later obviated. What will 
be the results of long term - a pos­
sible thirty years34 - alteration of 
human female metabolic rhythms? 
Of the disruption of the delicate 
and dynamic body equilibrium 
which physiologists have so long 
sought to understand and to pre­
serve? Perhaps not even time will tell. 
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